NEXT Life Sciences, the creator of the male contraceptive product Plan A, recently announced a successful $2.5 million funding round to advance the launch of its innovative solution into the market. The Family, a high-impact startup accelerator led the round with participation from Transform VC and a combination of angel investors and early-stage venture funds including entrepreneur Brock Pierce, Transform VC, StartupHealth, Pay It Forward Venture Capital, Particular Ventures, Keno Peer, Unpopular Ventures, and Joy Fund
Ryan Breslow, founder of The Family, a prominent startup accelerator, has also joined NEXT Life Sciences as a strategic advisor. He comments: “My mission for Family is to back top founders working on truly world-changing products and bring them to market more quickly,” said The Family Founder Ryan Breslow. “Plan A™ is unleashing bodily autonomy; it’s giving men the ability to share responsibility over long term contraceptive decisions. I’m all-in.”
“We couldn’t be more thrilled that The Family recognizes the potential impact for Plan A and we’re honored to welcome Ryan as a strategic advisor to help guide our team as we work to bring a revolutionary contraception to the market” said NEXT Life Sciences, Inc. Founder and CEO L. R. Fox. “With Plan A, our goal is to change lives by giving men the ability to participate equally in family planning, so that couples have a more equitable relationship and the tools needed to be intentional about their futures.”
Plan A is designed as a non-hormonal, long-acting, and reversible contraceptive for men. The product utilizes a hydrogel known as Vasalgel, which functions as a flexible filter to block sperm flow within the male vas deferens, effectively preventing pregnancy. NEXT acquired the exclusive worldwide license for Vasalgel in 2022 and aims to navigate the product through FDA authorization and subsequent market launch.
